EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2026

2017-06-01
Price :
Published : Jun-2017
No. of Pages : 45

EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2026

Summary

Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE (AHA, 2017).

Our epidemiologists forecast an increase in the diagnosed incident cases of VTE in the 7MM, from 896,377 cases in 2016 to 1,071,438 in 2026, at an Annual Growth Rate (AGR) of 1.95%.The number of VTE attacks is forecast to grow from 1,020,991 in 2016 to 1,224,696 in 2026 in the 7MM.

Our epidemiologists also forecast the number of medically ill patients at risk for VTE to increase in the 7MM from 23,021,689 in 2016 to 26,349,713 in 2026. In addition, epidemiologists forecast the number of total knee replacement and revision procedures to grow from 1,464,513 in 2016 to 1,743,614 in 2026. Furthermore, the number of hip replacements is forecast to grow 1,096,580 in 2016 to 1,313,439 in 2026. GlobalData epidemiologists have identified the predominant drivers of this market to be changes in country-specific incidence and procedure rates, as well as in the underlying demographic trends.

In 2016, the 7MM had 276,732 diagnosed incident cases of PE. This is expected to increase to 327,416 diagnosed incident cases of PE by 2026, at an Annual Growth Rate (AGR) of 1.83%. The US had 98,271 diagnosed incident cases of PE in 2016, which is expected to grow at an AGR of 2.55% to 123,299 cases in 2026. The 5EU had 169,711 cases in 2016 and is expected to grow to 194,881 cases by 2026. Of the 7MM, Spain is expected to have the largest AGR at 3.47%, with the number of diagnosed incident cases of PE increasing from 20,998 in 2016 to 28,283 cases by 2026.

Japan is expected to see the smallest increase in the number of cases, with an AGR of 0.56% from 2016-2026. In Spain, the change in diagnosed incidence of PE is driven by applying trending in the diagnosed PE incidence. In all other markets, the rates were held constant, and growth is a result of underlying demographic changes.

The report “EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2026” provides an overview of the risk factors, comorbidities, and the global and historical trends for VTE in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of PE, DVT, and VTE, as well as the number of VTE attacks, the number of medically ill discharges that are at risk for VTE, the number of primary total knee replacements and revisions, and the number of hip replacements, each of which are segmented by sex and age. Additionally, it includes a forecast for the number of recurrent VTE cases at one and 10 years after the incident event, and the number of diagnosed VTE cases with cancer as comorbidity.

Scope

– The Venous Thromboembolism (VTE) EpiCast Report provides an overview of the risk factors and global trends of VTE in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed incident cases of VTE, deep vein thrombosis, and pulmonary embolism segmented by sex and age (in five-year increments beginning at ages zero to four years and ending at 85 years and older) in these seven markets. Additionally, this report includes the number of VTE attacks, medically ill discharges at risk of VTE, primary total knee and hip replacements, recurrent VTE cases after one and 10 years, and diagnosed VTE cases with cancer as comorbidity.
– The VTE epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The VTE EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global VTE market.
– Quantify patient populations in the global VTE market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for VTE therapeutics in each of the markets covered.
– Identify the percentage of VTE cases with recurrence of VTE and percentage of VTE cases with cancer as comorbidity

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Pharmaceutical Packaging Equipment Market by Product (Aseptic Packaging, Blister, Strip, Bottle, Tube, Carton, Case Packer, Wrapping Machine, Palletizing, Labeling & Serialization), Type (Tablet, Powder, Cream, Syrup, Aerosol), Region – Global Forecast to 2025

The pharmaceutical packaging equipment market is expected to grow at a CAGR of 7.4% in the forecast period. The global pharmaceutical packaging equipment market size is projected to reach USD 10.4 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 7.4% from 2020 to 2025. The growth of the market is driven by the rapidly growing generic & biopharmaceutical markets, growth in OTC drug sales, rising need for flexible & integrated packaging equipment, increased offshore manufacturing in the pharmaceuticals market, and the introduction of regulatory standards on packaging & stringent norms against counterfeiting. However, factors such as the adoption of refurbished packaging equipment and the high cost of packaging equipment are expected to restrain market growth to a cer......
$4950

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective Summary Telemedicine is the use of electronic communication for the delivery of remote clinical care. It has been recognized as a critical strategy during the ongoing coronavirus disease 2019 (COVID-19) pandemic to limit the risk of person-to-person transmission of the virus as social distancing has become the norm. It is widely anticipated that COVID-19 may be the tipping point for telemedicine as the full potential of the technology is increasingly realized by patients, healthcare systems, and payers. As a result of the pandemic, regulations and policies governing reimbursement and use of telemedicine have changed significantly, leading to expanded access and an unprecedented demand for these services.......
$1495

Greece Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Greece Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Greece. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by Glob......
$1995

Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029

Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2029 Summary Meningococcal disease is an infection caused by Neisseria meningitidis bacteria, and, although relatively rare, is widely feared because of its high mortality rate even in otherwise healthy individuals. Serogroups A, B, C, W, and Y are the most common meningococcal types in the nine major markets (9MM) covered in this report (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, and China), and immunization of high-risk groups such as infants and adolescents provides the best protection against the infection. Immunization with conjugated meningococcal serogroup C (MenC) is routinely recommended for infants in the 5EU and Brazil, and immunization against serogroup ACWY (MenACWY vaccines) is recommended i......
$10995

Invasive Meningococcal Disease – Epidemiology Forecast to 2029

Invasive Meningococcal Disease - Epidemiology Forecast to 2029 Summary Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis). N. meningitidis is an encapsulated gram-negative bacterium that exists without complication in roughly 5-11% of adults and up to 25% of adolescents. However, if the bacterium moves beyond the nasopharynx and invades body tissue, serious illness can arise, usually in the form of meningitis or septicemia. Symptoms of disease can include fever, headache, stiff neck, nausea, photophobia, and fatigue, among others. The bacterium is spread by respiratory droplets through close or prolonged contact with an infected person and is not as contagious as the common cold or flu. In 2019, there wer......
$3995

Ulcerative Colitis – Epidemiology Forecast to 2029

Ulcerative Colitis - Epidemiology Forecast to 2029 Summary Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the large intestine and the rectum. The inflammation occurs only in the innermost layer of the lining of the intestine. In UC, ulcers develop on the surface of the bowel lining; these may bleed and produce mucus. If the inflammation is confined to rectum, it is called proctitis (Crohn's and Colitis Foundation of America, 2014; Crohn's and Colitis UK, 2019). UC can occur at any age, though most people are diagnosed in their mid-thirties. Men and women are equally likely to be affected, but older men are more likely to be diagnosed than older women. GlobalData epidemiologists utilized historical data obtained from peer-reviewed......
$3995

Contract Dose Manufacturing Industry by the Numbers – Composition, Size, Market Share and Outlook – 2020 Edition

Contract Dose Manufacturing Industry by the Numbers - Composition, Size, Market Share and Outlook - 2020 Edition Summary This expert trend report is a comprehensive look at the finished dose contract manufacturing landscape in 2020, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management. This report gives an important expert quantitative analysis on the contract dose manufacturing industry. Findings are based on the industry's most comprehensive database of the dose CMO industry (GlobalData's Pharma Intelligence Center Contract Service Providers Database) this analysis is driven by a ......
$4995

Egypt Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report, "Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Egypt. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalDa......
$1995

Duchenne Muscular Dystrophy Disease – Global Clinical Trials Review, H2, 2020

Duchenne Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Duchenne Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Critical Limb Ischemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Critical Limb Ischemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's propr......
$2500

Gestational Diabetes Disease – Global Clinical Trials Review, H2, 2020

Gestational Diabetes Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Gestational Diabetes Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Gestational Diabetes Clinical trials scenario. This report provides top line data relating to the clinical trials on Gestational Diabetes. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy